Table 1.
Patient demographics and characteristics.
| Total (N = 216) | No flare (N = 187) | Flare (N = 29) | ||
|---|---|---|---|---|
| Age (years) | Median 69 (48–90) years/old | Median 70 (49–90) years/old | Median 66 (48–77) years/old | |
| Race | White | 122 (56.5%) | 109 (58.3%) | 13 (44.8%) |
| Black | 81 (37.5%) | 65 (34.8%) | 16 (55.2%) | |
| Other | 13 (6.0%) | 13 (7.0%) | 0 (0%) | |
| Partner status | Partnered | 162 (75.0%) | 138 (73.8%) | 24 (82.8%) |
| Not partnered | 54 (25%) | 49 (26.2%) | 5 (17.2%) | |
| Work status | Work | 99 (45.8%) | 87 (46.5%) | 12 (41.4%) |
| Not employed | 117 (54.2%) | 100 (53.5%) | 17 (58.6%) | |
| Charlson comorbidity index (CCI) | CCI = 0 | 146 (64.6%) | 127 (67.9%) | 19 (65.5%) |
| CCI = 1 | 51 (23.6%) | 44 (23.5%) | 7 (24.1%) | |
| CCI ≥ 2 | 19 (8.8%) | 16 (8.6%) | 3 (10.3%) | |
| T-stage | T1c | 160 (74.1%) | 139 (74.3%) | 21 (72.4%) |
| T2a | 29 (13.4%) | 25 (13.4%) | 4 (13.8%) | |
| T2b | 20 (9.3%) | 17 (9.1%) | 3 (10.3%) | |
| T2c | 7 (3.2%) | 6 (3.2%) | 1 (3.4%) | |
| Gleason | 6 | 97 (44.9%) | 83 (44.4%) | 14 (48.3%) |
| 7 | 109 (50.5%) | 94 (50.3%) | 15 (51.7%) | |
| 8 | 10 (4.6%) | 10 (5.3%) | 0 (0%) | |
| D’Amico risk groups | Low | 83 (38.4%) | 71 (38.0%) | 12 (41.4%) |
| Intermediate | 111 (51.4%) | 95 (50.8%) | 16 (55.2%) | |
| High | 22 (10.2%) | 21 (11.2%) | 1 (3.4%) | |
| Prostate volume (cc) | Median 38 (11.6–138.7) | Median 37.6 (11.6–108) | Median 39.5 (13.8–138.7) | |
| PSA (ng/ml) | Median 5.8 (0.2–32.5) | Median 5.8 (0.2–32.5) | Median 5.7 (1.3–17.5) | |
| Testosterone (ng/dL) | Median 302.5 (20–1149) | 285.5 (20–1149) | 342 (40–692) | |
| AUA score | Median 7.5 (0–33) | Median 8 (0–33) | Median 7 (1–17) | |
| EPIC urinary domain | Median 88.9 (40.8–97.2) | Median 88.9 (40.8–97.2) | Median 94.4 (60.2–97.2) | |
| α1A Antagonist usage | 62 (28.7%) | 54 (28.9%) | 8 (27.6%) | |
| Procedures for BPH | 19 (8.8%) | 18 (9.6%) | 1 (3.5%) | |
| ADT | With ADT | 29 (13.4%) | 26 (13.9%) | 3 (10.3%) |
| SBRT dose (Gy) | 35 | 27 (12.5%) | 23 (12.3%) | 4 (13.8%) |
| 36.25 | 189 (87.5%) | 164 (87.7%) | 25 (86.2%) |
PSA, prostate-specific antigen; AUA, American Urological Association symptom score; EPIC, expanded prostate cancer index composite; BPH, benign prostate hyperplasia; ADT, androgen deprivation therapy; SBRT, stereotactic body radiation therapy.